Marius Andre Hybbestad Skow

• Farrell, Karen; Tandan, Meera; Santiago, Virginia Hernandez; Gagyor, Ildiko; Brænd, Anja Maria & Skow, Marius [Vis alle 10 forfattere av denne artikkelen] (2021). Treatment of uncomplicated UTI in males: a systematic review of the literature. British Journal of General Practice Open. ISSN 2398-3795. 26(2). doi: 10.3399/bjgpopen20X101140. Fulltekst i vitenarkiv
• Skow, Marius Andre Hybbestad; Vik, Ingvild & Høye, Sigurd (2020). Antibiotic switch after treatment with UTI antibiotics in male patients. Infectious Diseases. ISSN 2374-4235. 52(6), s. 405–412. doi: 10.1080/23744235.2020.1736329. Fulltekst i vitenarkiv
• Skow, Marius Andre Hybbestad; Bergmann, Natasha & Knop, Filip K. (2016). Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’. Diabetes, obesity and metabolism. ISSN 1462-8902. doi: 10.1111/dom.12685. Vis sammendrag

  The gut incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are secreted after meal ingestion and work in concert to promote postprandial insulin secretion and regulate glucagon secretion. GLP-1 also slows gastric emptying and suppresses appetite, whereas GIP seems to affect lipid metabolism. The introduction of selective GLP-1 receptor (GLP-1R) agonists for the treatment of type 2 diabetes and obesity has increased the scientific and clinical interest in incretins. Combining the body weight-lowering and glucose-lowering effects of GLP-1 with a more potent improvement of β cell function through additional GIP action could potentially offer a more effective treatment of diabetes and obesity, with fewer adverse effects than selective GLP-1R agonists; therefore, new drugs designed to co-activate both the GIP receptor (GIPR) and the GLP-1R simultaneously are under development. In the present review, we address advances in the field of GIPR and GLP-1R co-agonism and review in vitro studies, animal studies and human trials involving co-administration of the two incretins, as well as results from a recently developed GIPR/GLP-1R co-agonist, and highlight promising areas and challenges within the field of incretin dual agonists.

Se alle arbeider i Cristin